Haemonetics Corporation to Post Q3 2018 Earnings of $0.46 Per Share, Jefferies Group Forecasts (HAE)
Haemonetics Corporation (NYSE:HAE) – Stock analysts at Jefferies Group increased their Q3 2018 earnings per share estimates for Haemonetics Corporation in a research report issued to clients and investors on Tuesday. Jefferies Group analyst A. Petrone now expects that the medical instruments supplier will post earnings per share of $0.46 for the quarter, up from their prior forecast of $0.45. Jefferies Group has a “Buy” rating and a $48.00 price target on the stock. Jefferies Group also issued estimates for Haemonetics Corporation’s Q4 2018 earnings at $0.43 EPS, FY2018 earnings at $1.70 EPS, FY2019 earnings at $1.95 EPS, FY2020 earnings at $2.39 EPS, FY2021 earnings at $3.00 EPS and FY2022 earnings at $3.50 EPS.
Several other equities research analysts have also recently commented on HAE. Morgan Stanley boosted their target price on Haemonetics Corporation from $43.00 to $51.00 and gave the company an “equal weight” rating in a research note on Thursday. Barrington Research increased their price target on Haemonetics Corporation from $48.00 to $57.00 and gave the company an “outperform” rating in a research note on Wednesday. Craig Hallum reaffirmed a “hold” rating and issued a $50.00 price objective (up from $40.00) on shares of Haemonetics Corporation in a report on Wednesday. TheStreet raised Haemonetics Corporation from a “c” rating to a “b-” rating in a report on Monday, August 7th. Finally, BidaskClub raised Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $51.33.
Haemonetics Corporation (NYSE:HAE) traded down $0.40 during trading on Friday, hitting $54.52. The stock had a trading volume of 695,600 shares, compared to its average volume of 344,366. The firm has a market cap of $2,900.78, a price-to-earnings ratio of 33.69, a P/E/G ratio of 4.11 and a beta of 0.91. Haemonetics Corporation has a 52 week low of $36.44 and a 52 week high of $55.10. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.17 and a quick ratio of 1.72.
Haemonetics Corporation (NYSE:HAE) last released its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.07. The business had revenue of $225.40 million during the quarter, compared to analysts’ expectations of $219.12 million. Haemonetics Corporation had a return on equity of 11.16% and a net margin of 0.50%. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.38 earnings per share.
Large investors have recently added to or reduced their stakes in the stock. Arizona State Retirement System boosted its stake in Haemonetics Corporation by 1.1% in the second quarter. Arizona State Retirement System now owns 27,397 shares of the medical instruments supplier’s stock valued at $1,082,000 after buying an additional 300 shares in the last quarter. BlackRock Inc. boosted its stake in Haemonetics Corporation by 48,854.9% in the first quarter. BlackRock Inc. now owns 6,289,728 shares of the medical instruments supplier’s stock valued at $255,175,000 after buying an additional 6,276,880 shares in the last quarter. Aperio Group LLC boosted its stake in Haemonetics Corporation by 15.0% in the second quarter. Aperio Group LLC now owns 10,695 shares of the medical instruments supplier’s stock valued at $422,000 after buying an additional 1,393 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Haemonetics Corporation by 12.2% in the second quarter. Russell Investments Group Ltd. now owns 23,503 shares of the medical instruments supplier’s stock valued at $928,000 after buying an additional 2,553 shares in the last quarter. Finally, Kirr Marbach & Co. LLC IN boosted its stake in Haemonetics Corporation by 56.3% in the second quarter. Kirr Marbach & Co. LLC IN now owns 11,300 shares of the medical instruments supplier’s stock valued at $446,000 after buying an additional 4,070 shares in the last quarter.
Haemonetics Corporation Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.